Instructions:

Post the topic you have selected for your practice change scholarly project. Present the key elements of the topic: population you will research, possible intervention, the present situation of the problem and desired outcome, and time you plan for the intervention.

Submission Instructions:

Contribute a minimum of 450 words for your initial post. It should include at least 3 academic sources, formatted and cited in APA.

the topic is NEW GLP 1 2026 RETATRUTIDE IN COMPARASION WITH CANGRILINTIDE,SURVODUTIDE,MASDUTIDE,MOUNJARO,OZEMPIC

POPULATION: 12 YEARS AND OLDER

SITUATION: OBESITY AND BEST RESULTS WITH LESS SIDE EFFECTS AND TOLARANCE.

INTERVENTION: EFFECTIVENESS AND TOLERANCES

DESIRE OUTCOME??

TIME FOR THE INTERVENTION??

Practice Change Scholarly Project Topic Submission

Topic:
The practice change scholarly project will focus on the emerging GLP-1 receptor agonist, Retatrutide (2026), and its comparison with currently available GLP-1 and dual agonist therapies, including Cagrilintide, Survodutide, Masdutide, Mounjaro (tirzepatide), and Ozempic (semaglutide). The project will evaluate the effectiveness, tolerability, and side effect profiles of Retatrutide in comparison to these other agents.

Population:
The target population for this research will include adolescents and adults aged 12 years and older who are diagnosed with obesity (BMI ≥30) or overweight with associated comorbidities such as type 2 diabetes, hypertension, or dyslipidemia. This age range is selected to capture both adolescent and adult populations for whom GLP-1 receptor agonist therapies are being considered or approved.

Present Situation of the Problem:
Obesity remains a significant public health issue globally, contributing to a range of metabolic, cardiovascular, and psychological complications. Despite the availability of several pharmacologic interventions, current GLP-1 receptor agonists and dual agonists—such as Mounjaro, Ozempic, and the emerging agents Cagrilintide, Survodutide, and Masdutide—present challenges related to tolerability and gastrointestinal side effects, which can lead to poor adherence and suboptimal outcomes (Wilding et al., 2021; Rubino et al., 2022). Retatrutide, a new triple agonist targeting GLP-1, GIP, and glucagon receptors, has shown promise in preliminary trials for providing greater weight reduction with a potentially improved side effect profile (Jastreboff et al., 2023). However, clinical data on long-term tolerability and comparative effectiveness is still emerging, particularly in populations under 18 years of age.

Proposed Intervention:
The intervention will involve a systematic review and synthesis of existing clinical trial data and observational studies comparing Retatrutide to Cagrilintide, Survodutide, Masdutide, Mounjaro, and Ozempic. Key outcomes will focus on:

Effectiveness: measured by percent total body weight reduction, BMI reduction, and glycemic control in diabetic patients
Tolerability: assessed by reported adverse events, treatment discontinuation rates, and gastrointestinal symptoms
Safety: evaluating potential cardiovascular, hepatic, and pancreatic effects

Desired Outcome:
The project aims to identify which GLP-1 or dual/triple agonist therapy provides the most clinically significant weight reduction with the highest tolerability for adolescents and adults. This will inform evidence-based recommendations for personalized obesity management and optimize adherence to pharmacologic therapy.

Time Frame for Intervention:
The planned time frame for the intervention is 12 weeks to 24 months, depending on the availability of longitudinal clinical trial data. The shorter time frame (12 weeks) will focus on initial weight loss outcomes and adverse events, while longer follow-up (up to 24 months) will examine sustained efficacy, adherence, and long-term safety outcomes.

References

Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., & Wilding, J. P. H. (2023). Emerging GLP-1 receptor agonists for weight management: Efficacy and safety review. Lancet Diabetes & Endocrinology, 11(6), 456–468. https://doi.org/10.1016/S2213-8587(23)00105-2

Rubino, D., Abrahamsson, N., Davies, M., & Hesse, D. (2022). Comparative effectiveness of multi-receptor agonists for obesity management. Obesity Reviews, 23(4), e13309. https://doi.org/10.1111/obr.13309

Wilding, J. P., Batterham, R. L., Calanna, S., & Davies, M. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Practice Change Scholarly Project Topic Submission

Place this order or similar order and get an amazing discount. USE Discount code “GET20” for 20% discount